APAC Cell Based Assay Market

APAC Cell-Based Assay Market Size (2024 to 2029)

The Cell-Based Assay Market size in the Asia Pacific was worth USD 2.80 billion in 2024 and is estimated to be growing at a CAGR of 12.6% to reach USD 5.07 billion by 2029. Asia is expected to show a high growth rate in the cell-based assays market in the next few years owing to technological development, an increase in investments in R&D includes life science research and drug discovery outsourcing in the region.

Factors such as the growing prevalence of chronic diseases like cancer, cardiovascular, diabetes, and nerve disorders are likely to fuel cell-based assay market growth. An escalating necessity for cell-based assays has risen significantly as of growing cell-based applications for drug invention, and advancements in technology are further propelling the market growth of the region.

The significant costs associated, the shortage of skilled professionals and lack of awareness among the professionals are majorly showing a negative impact on the APAC cell-based assay market. Mistrust and doubtful about the long-term advantages provided by the cell-based market technique may obstruct the growth.

This research report segmented and sub-segmented into the following categories.

• By Type Of Product: Cell Lines, Assay Ready Kits, Cell Culture Kits, Reagents & Consumables, And Ligands & Inhibitors
• By Technology: Automated Handling, Flow Cytometry, Label-Free Detection, High Content Screening, And High Throughput Screening
• By Application: Drug Discovery and ADME Research
• By End Users: Academia, Biotechnology, Pharmaceuticals, And CRO
• By Country: India, China, Japan, South Korea, Australia, New Zealand, Thailand, Malaysia, Vietnam, Philippines, Indonesia, Singapore and Rest of APAC

Regionally, the APAC region is deemed to have the highest CAGR growth rate in the global cell-based assay market during the historical period because of growing investments for research and development activities by the government and other organizations, raising infrastructure development this region. India and Japan are expected to have the highest growth rate in the analysis period.

China is expected to rule out the APAC region's cell-based assays market as a result of a growing number of pharmaceutical and biotechnology industry sectors, which raises the demand for cell-based assay, which is predicted to fuel the market growth in this region.

Japan is anticipated to grow within a short period within this region of the cell-based assay market over the review period owing to an increasing number of cancer cases, increasing investments in healthcare services, increasing expenses by the government and increasing requirement for toxicity in examination and identification of drugs which boosts the cell-based assays market growth during the historical period.

The Indian cell-based assays market is predicted to witness healthy CAGR during the forecast period owing to a growing number of cases of chronic diseases and increasing obtainment of excellent research amenities throughout the analysis period.

Prominent companies dominating the APAC Cell-Based Assay Market profiled in this report are Thermo Fisher Scientific Inc., Becton & Dickinson and Company, Merck & Co. Inc., Cell Signalling Technology Inc., PerkinElmer Inc., Danaher Corporation, General Electric Company, Cisbio Bioassays, DiscoveRx, Ametek Inc., Bio-Rad Laboratories, Roche Diagnostics, GE Healthcare, and Promega Corporation.